Opinion|Videos|August 12, 2024
Overcoming Immunotherapy Resistance: Identifying Non-Responders and Novel Approaches
The panel shares clinical practices for overcoming immunotherapy resistance in patients with non-small cell lung cancer.
Advertisement
Episodes in this series
Video content above is prompted by the following questions:
- What gaps remain in identifying likely non-responders to immunotherapy to guide alternative treatments?
- How does the toxicity profile of immuno-oncology regimens compare to standard chemotherapy options?
- Are there ongoing trials or research on novel combination approaches to overcome resistance and improve immunotherapy efficacy?
Advertisement
Related to this article
Shiven B. Patel, MD, MBA, shares strategies for closing biomarker testing gaps, including among patients with non–small cell lung cancer.
Advertisement
Advertisement
Trending on AJMC
1
Delayed Dupilumab Raises Asthma Costs 32%: Nicola Hanania, MD
2
Across the US, Obesity Care Still Lacks an Owner
3
Aspirin's CRC Benefit Narrows to PIK3CA Exon 9/20 Mutations
4
A Patient-Centered Reconstruction of 340B in Oncology: Transparency, Equity, and Site-of-Care Accountability
5